Ann: MSB Clinical Program Update For MPC-150-IM In Heart Failure, page-2

Data Monitoring Committee (DMC) has performed another, scheduled review of the CHF trial data and recommended continuation of the trial without modification. Enrollment of this Phase 3 trial is expected to be completed by the end of 2018.

LVAD National Institutes for Health (NIH) Phase 2 trial has also completed enrollment with 12-month data read-out expected in the next quarter (Q3 CY18). Mesoblast is actively pursuing a potential accelerated entry pathway for MPC-150-IM into the cardiovascular market that may be provided by RMAT designation.

So, my take on this is both of these Tier 1 trials are confirmed on track with results coming in expected time-frames.